macozinone   Click here for help

GtoPdb Ligand ID: 13055

Synonyms: PBTZ169
Compound class: Synthetic organic
Comment: Macozinone (PBTZ169) is the lead from a series of piperazine-containing benzothiazinones [1]. It has potent antimycobacterial activity and is under clinical evaluation as a treatment for tuberculosis (TB). Macozinone is an inhibitor of decaprenylphosphoryl-beta-D-ribose oxidase (DprE1), an essential mycobacterial cell wall biosynthesis enzyme [1].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 0
Rotatable bonds 5
Topological polar surface area 104.35
Molecular weight 456.48
XLogP 4.49
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C1CCC(CC1)CN2CCN(CC2)C3=NC(=O)C4=CC(=CC(=C4S3)[N+](=O)[O-])C(F)(F)F
Isomeric SMILES C1CCC(CC1)CN2CCN(CC2)C3=NC(=O)C4=C(S3)C(=CC(=C4)C(F)(F)F)[N+](=O)[O-]
InChI InChI=1S/C20H23F3N4O3S/c21-20(22,23)14-10-15-17(16(11-14)27(29)30)31-19(24-18(15)28)26-8-6-25(7-9-26)12-13-4-2-1-3-5-13/h10-11,13H,1-9,12H2
InChI Key BJDZBXGJNBMCAV-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Macozinone is under clinical evaluation as a treatment for tuberculosis. Several Phase 1 studies have been completed (NCT03036163, NCT03423030, NCT03776500, NCT04150224) while a Phase 2 trial (NCT03334734) to evaluate early antibacterial activity was terminated (February 2018) due to slow enrollment.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03334734 Phase 2a Study of PBTZ169 Phase 2 Interventional Nearmedic Plus LLC Study was terminated due to slow enrollment.
NCT03036163 Phase 1 Study of PBTZ169 Phase 1 Interventional Nearmedic Plus LLC
NCT04150224 Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169 Phase 1 Interventional Nearmedic Plus LLC
NCT03776500 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ169 in Multiple Dosing Phase 1 Interventional Innovative Medicines for Tuberculosis
NCT03423030 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ169 Formulation Phase 1 Interventional Innovative Medicines for Tuberculosis